<DOC>
	<DOC>NCT01468077</DOC>
	<brief_summary>This multi-center, randomized, parallel-group, active-controlled, open-label study will evaluate the safety and efficacy of a shortened RoActemra/Actemra (tocilizumab) infusion time compared to the normal infusion time. Patients will be randomized to 8 mg/kg RoActemra/Actemra infusion of 31 minutes every 4 weeks or to RoActemra/Actemra 8 mg/kg infusion of 60 minutes every 4 weeks. The anticipated time on study treatment is 24 weeks.</brief_summary>
	<brief_title>A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adult patients, at least 18 years of age, inclusive Diagnosis of rheumatoid arthritis of at least 6 months duration Moderate to severe active rheumatoid arthritis (DAS28 &gt;/=3.2) Patients received at least 1 diseasemodifying antirheumatic drug (DMARD) and/or 1 or more TNFalfainhibitors over a period of at least 8 weeks Major surgery (including joint surgery) within 8 weeks prior to screening or planned surgery within 6 months following randomization Rheumatic autoimmune disease other than rheumatoid arthritis Prior history of or current inflammatory joint disease other than rheumatoid arthritis Functional class IV (ACR criteria) History of severe allergic reaction to human, humanized or murine monoclonal antibodies Known active current or history of recurrent infection (including tuberculosis) Primary or secondary immunodeficiency (history of or currently active) Body weight &gt;150 kg Previous treatment with any celldepleting therapies Previous treatment with tocilizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>